2025
Johnson & Johnson to Separate Orthopaedics Business
Johnson & Johnson; Orthopaedics; DePuy Synthes; MedTech; Separation
Geron Corporation Announces Executive Leadership Transitions and Appointments
Geron Corporation; executive leadership; appointments; departures; commercial strategy; RYTELO; Harout Semerjian; Ahmed ElNawawi; Andrew Grethlein; Jim Ziegler
FDA Delays Denali’s Hunter Syndrome Therapy Decision by Three Months
FDA delay; Denali Therapeutics; Hunter syndrome; tividenofusp alfa; MPS II; Biologics License Application (BLA); review extension; clinical pharmacology; major amendment; accelerated approval
REACtiVe-2 Phase 1 Data Show Immune Activation in Pancreatic Cancer Treatment with Mitazalimab
Mitazalimab; REACtiVe-2; Metastatic Pancreatic Cancer; Immune Activation
Novo Nordisk Ends Cell Therapy Research Amid Major Restructuring
Novo Nordisk; cell therapy; restructuring; job cuts; diabetes; cost-cutting; R&D strategy; biotech; obesity; partnership cancellations
FDA Drug Approvals in 2025 Remain Within Recent Averages Amid Agency Upheaval
FDA; drug approvals; 2025; new molecular entities; CDER; CBER; trends; novel drugs
No Recent News Specifically About ‘Click here to continue reading’
click here to continue reading; news; recent news; web navigation; internet phrase
AstraZeneca Reaches Drug Pricing Deal with White House, Becomes Second Pharma to Do So
AstraZeneca; White House; drug pricing; Medicaid; TrumpRx; most-favored-nation pricing; tariffs; Pfizer; drug discounts
Regeneron Heads to FDA Seeking Approval for Game-Changing Hearing Loss Gene Therapy
Regeneron; hearing loss; gene therapy; DB-OTO; FDA approval; OTOF gene; CHORD trial
Ypsomed Invests $248 Million to Establish First U.S. Manufacturing Site in North Carolina
Ypsomed; manufacturing expansion; U.S. facility; Holly Springs; North Carolina; CHF 200 million; self-injection systems; job creation; global growth strategy; medical technology